Global Monoclonal Antibody Market Report

The global demand for Monoclonal Antibody Market is presumed to reach the market size of nearly USD 269.15 Billion by 2032 from USD 236.23 Billion in 2023 with a CAGR of 1.46% under the study period 2024-2032.

Monoclonal antibodies (mAb or moAb) are a protein type made in the laboratory that can bind to substances in the body. They are identical immunoglobulins generated from a single B-cell clone. Monoclonal antibodies are employed to treat many diseases and can be used alone or carry drugs, toxins, or radioactive substances. There are many varieties of monoclonal antibodies and different ways of making them, and they are named based on how they are made of chimeric, murine, humanized, and human. Monoclonal antibodies recognize unique epitopes, or binding sites, on a single antigen. They act like human antibodies in the immune system.

Market Dynamics

Monoclonal antibodies (mAb or moAb) have become an important tool in biochemistry, molecular biology, and medicine. Rising incidence of chronic diseases and cancer, increasing regulatory approvals, the launch of therapies, and growing R&D primarily drive the global monoclonal antibody market. Chronic diseases and cancer are the leading cause of death worldwide. According to the World Health Organization estimates, chronic diseases are responsible for around two-thirds of all deaths worldwide. In 2020, cancer caused the death of nearly 10 million people. Monoclonal antibodies have gained attention with the rise of the COVID-19 pandemic. They have progressed to allow more widespread use. Monoclonal antibodies offer many benefits to the pharmaceutical industry and treat the COVID-19 pandemic, including short production time, low cost, highly stable and tolerant of pH or buffer changes, high affinity, and tolerance of minor antigen changes. Monoclonal antibodies are identified as a promising approach for treating COVID-19 patients. Robust research is being carried out to use it to treat COVID-19. However, higher costs associated with a monoclonal antibody, strict regulatory measures, low awareness about monoclonal antibody, and lack of research is likely to hamper the market growth.

The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Monoclonal Antibody. The growth and trends of Monoclonal Antibody industry provide a holistic approach to this study.

Market Segmentation

This section of the Monoclonal Antibody market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Source

• Murine
• Chimeric
• Humanized
• Human

By Production

• In Vivo
• In Vitro

By Application

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Neurological Diseases
• Others

By End-use

• Hospitals
• Specialty Centers
• Others

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Monoclonal Antibody market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

Global Monoclonal Antibody Market Share by Region (Representative Graph)

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Monoclonal Antibody market include Novartis AG, Pfizer Inc, GlaxoSmithKline Plc, Amgen Inc., Merck & Co. Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca Plc, Eli Lilly And Company, Johnson & Johnson Services Inc., Bayer AG, Bristol Myers Squibb, F. Hoffman-La Roche Ltd., Viatris Inc., Biogen Inc., Thermo Fisher Scientific Inc., Novo Nordisk A/S, Sanofi S.A., Merck KGaA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.